Sareum Holdings PLC Sierra Oncology to Present at ASCO Annual Meeting
May 25 2017 - 2:02AM
RNS Non-Regulatory
TIDMSAR
Sareum Holdings PLC
25 May 2017
(AIM: SAR) 25 May 2016
SAREUM HOLDINGS PLC
("Sareum" or "the Company")
Sierra Oncology to Present Chk1 Clinical Trial Enhancements
at ASCO Annual Meeting
Sareum Holdings plc (AIM:SAR), the specialist cancer drug
discovery and development company, notes an announcement made by
Sierra Oncology, Inc. yesterday stating that it will be presenting
two Trials in Progress posters describing the innovative Phase 1
clinical designs for its Chk1 inhibitor, SRA737, at the 2017
American Society of Clinical Oncology (ASCO) Annual Meeting, being
held in Chicago on June 5(th) .
These ongoing trials were recently amended to include cohort
expansions of prospectively selected patients with tumors
identified to have genetic abnormalities that are thought to confer
sensitivity to Chk1 therapy.
The full announcement can be found on Sierra Oncology's IR
website(*) .
Dr Tim Mitchell, CEO of Sareum, commented: "This announcement
shows the interest by the scientific community in Sierra's
leading-edge strategy that builds on Chk1's specific biological
role in cancer, which has been made possible by recent developments
in genetic analysis and is part of the progress towards
personalised anti-cancer therapies. We look forward to keeping
investors abreast of Sierra's progress and we can expect a further
update from Sierra in early 2018."
Sierra Oncology holds exclusive and worldwide rights for the
Chk1 inhibitor, SRA737, having licensed the programme from Sareum's
co-investment partner, the CRT Pioneer Fund in September 2016. This
announcement does not trigger any milestone payments under the
terms of the agreement.
*http://investor.sierraoncology.com/2017-05-24-Sierra-Oncology-to-Present-Innovative-Clinical-Trial-Enhancements-Leveraging-Chk1-Synthetic-Lethality-in-Two-Posters-at-ASCO-Annual-Meeting
For further information, please contact:
Sareum Holdings plc
Tim Mitchell 01223 497 700
WH Ireland Limited (Nominated Adviser and
Co-Broker)
Chris Fielding / Nick Prowting 020 7220 1666
Hybridan LLP (Co-Broker)
Claire Noyce 020 3764 2341
The Communications Portfolio
(Sareum Media enquiries)
Ariane Comstive
Ariane.comstive@communications-portfolio.co.uk 07785 922 354
Notes for editors:
Sareum is a drug discovery and development company delivering
targeted small molecule therapeutics, focusing on cancer and
autoimmune disease, and licensing them to pharmaceutical and
biotechnology companies at the preclinical or early clinical trials
stage.
Sareum operates an outsourced research model, working with
international collaborators and a world-wide network of research
providers. Its most advanced programme (Chk1) commenced clinical
trials in May 2016 and was licensed to NASDAQ-listed Sierra
Oncology in September 2016.
SKIL(R) (Sareum Kinase Inhibitor Library) is Sareum's drug
discovery technology platform that has so far produced the
Company's Aurora+FLT3 and TYK2 kinase cancer and autoimmune disease
research programmes, which are in the IND-enabling preclinical and
lead optimisation stages respectively. SKIL(R) can also generate
drug research programmes against other kinase targets.
Sareum Holdings plc is listed on the AIM market of the London
Stock Exchange, trading under the symbol SAR. For further
information, please visit www.sareum.co.uk
ASCO 2017 Poster Presentations
Title: A phase I study of SRA737 (formerly known as CCT245737)
administered orally in patients with advanced cancer.
Trials in Progress Abstract: #TPS2607
Poster: #93b
Poster Session: Developmental Therapeutics - Clinical
Pharmacology and Experimental Therapeutics
Date and Time: Monday, June 5, 2017, 8:00 - 11:30am CT
Location: McCormick Place, Event room: Hall A, 2301 S King Dr.,
Chicago, Illinois
Title: A phase I study of oral SRA737 (formerly CCT245737) given
in combination with gemcitabine plus cisplatin or gemcitabine alone
in patients with advanced cancer.
Trials in Progress Abstract: #TPS2613
Poster: #96b
Poster Session: Developmental Therapeutics - Clinical
Pharmacology and Experimental Therapeutics
Date and Time: Monday, June 5, 2017, 8:00 - 11:30am CT
Location: McCormick Place, Event room: Hall A, 2301 S King Dr.,
Chicago, Illinois
The posters will be available on June 5, 2017 on the company's
website at www.sierraoncology.com
- Ends -
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAPGUBAAUPMGWC
(END) Dow Jones Newswires
May 25, 2017 02:02 ET (06:02 GMT)
Sareum (LSE:SAR)
Historical Stock Chart
From Apr 2024 to May 2024
Sareum (LSE:SAR)
Historical Stock Chart
From May 2023 to May 2024